NEW YORK (GenomeWeb) – Biocept today announced a preferred provider collaboration and services agreement with Oregon Health & Sciences University granting the university the rights to offer Biocept's Target Selector liquid biopsy testing services throughout Oregon.
The partners also plan to engage in technology transfer that would allow OHSU to use Target Selector assays in house, and to act as a secondary laboratory for Biocept's research and testing services. Biocept and OHSU also said they plan to codevelop liquid biopsy assay technologies and platform capabilities, including highly sensitive, multiplexed assay panels for molecular biomarker detection and assessment.
The partners also expect to engage in additional R&D commercial pilot projects. Financial and other terms of the agreement were not disclosed. OHSU is acting on behalf of the OHSU Knight Cancer Institute on the deal.